Skip to Main Content

Paper Details

Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.
Bone Marrow Transplant
40
2022
AML, CBF, Venetoclax, aza, azacitidine, non, non-CBF AML, patients, stem cell, ven, venetoclax
Author NameAffiliation
Daniel A PollyeaUniversity of Colorado
Amanda WintersUniversity of Colorado
Veronica Clavijo JordanUniversity of Colorado
Veronica Clavijo JordanUniversity of Colorado
Diana AbbottUniversity of Colorado
Clayton A SmithUniversity of Colorado
  • 1 - 6

Datasets

Release 1.2